Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Could New Antibiotics Threaten Public Health?

By Biotechdaily staff writers
Posted on 18 Jun 2003
The large range of antibiotics currently under development may pose a threat to public health by weakening the body's natural defenses against infection, according to an article by two biologists in the June 2003 issue of Microbiology.

The new antibiotics are attracting interest as a major new weapon in the campaign against bacterial infection, even though both experimental evidence and theoretical arguments suggest this may not be so, note the authors.

"It is claimed that bacteria will be unable to evolve resistance to them because they attack the ‘Achilles heel' of bacterial cell-wall structure,” explains Graham Bell, an evolutionary biologist at McGill University (Montreal, Canada). More...
However, it this is true, "the introduction of these substances into general use may provoke the evolution of resistance to our defense proteins.” The article was co-authored by Pierre-Henri Gouyon, of the Ecologic Laboratory at the University of Paris (France).

Because the potential benefits of such antibiotics have been emphasized without drawing attention to the likelihood that resistance will evolve or to the consequences for human populations should that happen, the authors believe the development of this new category of antibiotics should be restrained "until the likely response of bacterial populations is more clearly understood.” They argue that the evolutionary consequences of new treatments involving the health of whole populations must be considered in the regulatory process.

If further investigation shows that bacteria will not build resistance to the new antibiotics, then the path will be clear for their introduction into wider circulation as a potentially valuable weapon against infectious disease. However, mathematical models already indicate that resistance is quite likely to spread, and therefore caution must be exercised until further research is conducted.




Related Links:
McGill University.

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Electrolyte Analyzer
BKE-B
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.